CEO Angelos Stergiou was paid $1,877,810 in fiscal year 2025, ↑ up 57.8% from fiscal year 2024, the 50th percentile of its disclosed peer group (SEC filing 0001104659-26-047693 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,877,810 ↑ Angelos Stergiou total, FY2025 | 50th CEO pay percentile vs peers | — CEO-to-median pay ratio | 76.89% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
SLS's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Angelos Stergiou | $676,000 | $0 | $477,107 | $327,695 | $390,390 | $0 | $6,618 | $1,877,810 |
| President and Chief Executive Officer | ||||||||
| Dragan Cicic | 451,234 | 0 | 185,071 | 143,990 | 193,128 | 0 | 18,372 | 991,795 |
| Senior Vice President, Chief Development Officer | ||||||||
| John Burns | 429,605 | 0 | 185,071 | 143,990 | 185,589 | 0 | 15,398 | 959,653 |
| Senior Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Angelos Stergiou | $1,877,810 | $1,189,773 | $1,752,638 | ↑ +688,037 |
| Dragan Cicic | 991,795 | — | — | — |
| John Burns | 959,653 | 680,778 | 797,708 | ↑ +278,875 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Sellas Life Sciences Group's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SLS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Angelos Stergiou | CEO | $1,877,810 |
| Dragan Cicic | Executive | $991,795 |
| John Burns | CFO | $959,653 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| David A. Scheinberg | Independent Director | $92,917 |
| Jane Wasman | Independent Director | $92,917 |
| John Varian | Chair of the Board | $120,917 |
| Katherine Bach Kalin | Independent Director | $92,917 |
| Robert L. Van Nostrand | Independent Director | $92,917 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Angelos Stergiou | RSU | 192,750 | — | $726,668 |
| Dragan Cicic | Option | 169,500 | 0.95 | — |
| Angelos Stergiou | Option | 124,219 | 0.52 | — |
| John Burns | RSU | 23,500 | — | 88,595 |
| Dragan Cicic | Option | 33,854 | 0.52 | — |
| Angelos Stergiou | RSU | 14,500 | — | 54,665 |
| Dragan Cicic | Option | 1,016 | 5.34 | — |
| Dragan Cicic | RSU | 25,000 | — | 94,250 |
| Dragan Cicic | RSU | 4,000 | — | 15,080 |
| Angelos Stergiou | Option | 3,438 | 5.34 | — |
| Dragan Cicic | RSU | 84,750 | — | 319,508 |
| John Burns | Option | 750 | 5.34 | — |
| John Burns | Option | 21,875 | 3.34 | — |
| Angelos Stergiou | Option | 63,438 | 3.34 | — |
| Angelos Stergiou | RSU | 95,000 | — | 358,150 |
| John Burns | RSU | 84,750 | — | 319,508 |
| John Burns | RSU | 15,000 | — | 56,550 |
| Angelos Stergiou | RSU | 79,500 | — | 299,715 |
| Dragan Cicic | RSU | 22,500 | — | 84,825 |
| Dragan Cicic | Option | 16,042 | 3.34 | — |
| John Burns | RSU | 5,000 | — | 18,850 |
| Angelos Stergiou | Option | 385,750 | 0.95 | — |
| John Burns | Option | 169,500 | 0.95 | — |
| John Burns | Option | 39,063 | 0.52 | — |
The compensation of our named executive officers is designed to enable us to attract and retain talented and experienced executives capable of leading the Company successfully in a competitive environment. We believe that our compensation policies and decisions are focused on pay-for-performance principles, are strongly aligned with our stockholders' interests, and are effective in achieving the overall objectives of our compensation program.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Radford, a division of Aon Hewitt |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-16 | 52,930,792 | 15,906,732 | 2,196,654 | 76.89% | Passed |
| 2025 | 2025-06-17 | 29,589,249 | 12,767,791 | 1,128,179 | 69.86% | Passed |
| 2024 | 2024-06-20 | 5,992,510 | 4,808,398 | 554,175 | 55.48% | Passed |
| 2023 | 2023-06-20 | 4,772,547 | 3,079,811 | 135,401 | 60.78% | Passed |
| 2022 | 2022-06-08 | 4,224,292 | 1,575,977 | 77,834 | 72.83% | Passed |
| 2021 | 2021-06-08 | 2,383,795 | 849,429 | 200,418 | 73.73% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-16 | 76.89%a |
| 2025 | 2025-06-17 | 69.86%b |
| 2024 | 2024-06-20 | 55.48%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will count towards a quorum but will have no effect on the outcome of this Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John VarianIndependent · Board Chair · Audit · Compensation · Science | $94,000 | $11,906 | $15,011 | — | — | $120,917 |
| David A. ScheinbergIndependent · Compensation · Science (Chair) | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Robert L. Van NostrandIndependent · Audit · Nominating and Corporate Governance | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Jane WasmanIndependent · Audit · Nominating and Corporate Governance (Chair) | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Katherine Bach KalinIndependent · Compensation (Chair) · Nominating and Corporate Governance | 66,000 | 11,906 | 15,011 | — | — | 92,917 |
| Angelos M. StergiouEmployee director · Science | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,000 / 18,000 / 18,000 |
| Stock ownership guideline | Retail stockholders and Glass Lewis, however, requested more details on our stock ownership guidelines. As a result of this feedback, the Company has provided a summary of the stock ownership guidelines in this Proxy Statement |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $358,000 |
| Equity awards (grant-date value) | $59,530 |
| All other compensation | $0 |
| Total cost of the board | $417,530 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Sellas Life Sciences Group names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Sellas Life Sciences Group.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Corvus Pharmaceuticals, Inc. | 2025 | Richard Miller | $36,566 | $0 | $6,989,000 | $0 | $7,031,566 |
| 2 | Compass Therapeutics | 2025 | Thomas Schuetz | 630,000 | 0 | 4,065,000 | 0 | 5,097,150 |
| 3 | Verastem, Inc. | 2025 | Daniel Paterson | 674,000 | 1,161,661 | 0 | 489,324 | 2,349,975 |
| 4 | Elevation Oncology, Inc. | 2024 | Joseph Ferra | 620,833 | 277,000 | 1,117,793 | 294,896 | 2,326,372 |
| 5 | Sellas Life Sciences Group | 2025 | Angelos Stergiou | 676,000 | 477,107 | 327,695 | 390,390 | 1,877,810 |
| 6 | Actinium Pharmaceuticals, Inc. | 2025 | Sandesh Seth | 762,320 | 0 | 0 | 0 | 1,187,320 |
| 7 | Cue Biopharma, Inc. | 2025 | Usman Azam | 143,077 | 0 | 1,042,313 | 0 | 1,185,639 |
| 8 | Syros Pharmaceuticals | 2023 | Conley Chee | 479,092 | 369,460 | 0 | 192,455 | 1,041,697 |
| — | Cellectar Biosciences, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Checkpoint Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | PDS Biotechnology Corporation | — | — | — | — | — | — | not in coverage universe |
| — | BeyondSpring Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Cidara Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Leap Therapeutics, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Equillium, Inc. | — | — | — | — | — | — | not in coverage universe |
| — | Immunic, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Sellas Life Sciences Group | not disclosed | not disclosed | not disclosed | Radford, a division of Aon Hewitt |
| Actinium Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | StreeterWyatt Analytics LLC |
| BeyondSpring Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cellectar Biosciences, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Checkpoint Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Cidara Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Compass Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Corvus Pharmaceuticals, Inc. | not disclosed | Option 100 | not disclosed | not disclosed |
| Cue Biopharma, Inc. | not disclosed | Option 100 | not disclosed | Radford, an AON Hewitt company |
| Elevation Oncology, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards |
| Equillium, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Immunic, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Leap Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| PDS Biotechnology Corporation | not disclosed | not disclosed | not disclosed | not disclosed |
| Syros Pharmaceuticals | not disclosed | not disclosed | not disclosed | Compensia Inc. |
| Verastem, Inc. | not disclosed | not disclosed | not disclosed | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Angelos Stergiou | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Summary Compensation Table”. As printed: 1,877,810. Filing ↗ |
| 2 | Section 01, Dragan Cicic | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Summary Compensation Table”. As printed: 991,795. Filing ↗ |
| 3 | Section 01, John Burns | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Summary Compensation Table”. As printed: 959,653. Filing ↗ |
| 4 | Section 08, John Varian | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Director Compensation”. As printed: 120,917. Filing ↗machine: span 652056–652063 |
| 5 | Section 08, David A. Scheinberg | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Director Compensation”. As printed: 92,917. Filing ↗machine: span 659790–659796 |
| 6 | Section 08, Robert L. Van Nostrand | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Director Compensation”. As printed: 92,917. Filing ↗machine: span 654631–654637 |
| 7 | Section 08, Jane Wasman | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Director Compensation”. As printed: 92,917. Filing ↗machine: span 657219–657225 |
| 8 | Section 08, Katherine Bach Kalin | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Director Compensation”. As printed: 92,917. Filing ↗machine: span 662387–662393 |
| 9 | Section 08, Angelos M. Stergiou | DEF 14A | 2026-04-23 | 0001104659-26-047693 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 10 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001104659-26-075775 | Item 5.07 · say-on-pay result. As reported: 76.89% (votes for as printed: 52,930,792). Filing ↗ |
| 11 | Section 06, 2025 vote | Form 8-K | 2025-06-18 | 0001104659-25-060704 | Item 5.07 · say-on-pay result. As reported: 69.86% (votes for as printed: 29,589,249). Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-06-21 | 0001104659-24-073957 | Item 5.07 · say-on-pay result. As reported: 55.48% (votes for as printed: 5,992,510). Filing ↗ |
| 13 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 14 | Section 09b board cost (computed) | Computed | — | — | Cash 358,000 + equity 59,530 + all other 0 = 417,530, summed across the director compensation table rows.machine: formula: Σ = 417,530 |
| 15 | Corvus Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001104659-26-048595 | CEO total compensation as printed in Corvus Pharmaceuticals, Inc.'s own proxy. As printed: 7,031,566. Filing ↗ |
| 16 | Compass Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017649 | CEO total compensation as printed in Compass Therapeutics's own proxy. As printed: 5,097,150. Filing ↗machine: r2 · c21 · span 303582–303591 |
| 17 | Verastem, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001104659-26-041506 | CEO total compensation as printed in Verastem, Inc.'s own proxy. As printed: 2,349,975. Filing ↗ |
| 18 | Elevation Oncology, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005413 | CEO total compensation as printed in Elevation Oncology, Inc.'s own proxy. As printed: 2,326,372. Filing ↗machine: r5 · c14 · span 446279–446288 |
| 19 | Sellas Life Sciences Group (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047693 | CEO total compensation as printed in Sellas Life Sciences Group's own proxy. As printed: 1,877,810. Filing ↗ |
| 20 | Actinium Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-10-16 | 0001213900-26-110022 | CEO total compensation as printed in Actinium Pharmaceuticals, Inc.'s own proxy. As printed: 1,187,320. Filing ↗machine: r1 · c17 · span 504881–504890 |
| 21 | Cue Biopharma, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-108301 | CEO total compensation as printed in Cue Biopharma, Inc.'s own proxy. As printed: 1,185,639. Filing ↗machine: r2 · c12 · span 458480–458489 |
| 22 | Syros Pharmaceuticals, Section 10b CEO total | 10-K | 2024-04-23 | 0001193125-24-105876 | CEO total compensation as printed in Syros Pharmaceuticals's own proxy. As printed: 1,041,697. Filing ↗machine: r2 · c27 · span 248160–248169 |
| 23 | Section 10a, Verastem, Inc. reciprocity | DEF 14A | — | 0001104659-26-041506 | Verastem, Inc.'s most recent proxy was read; its disclosed peer group does not include Sellas Life Sciences Group. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.